Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1008596 | 0.98 | TSHR (0.40) | DUTTSHRHIF1AFAAHTRPV1 | |
| SCHEMBL27241090 | 0.98 | TSHR (0.40) | DUTTSHRHIF1AFAAHTRPV1 | |
| SCHEMBL2917304 | 0.98 | TSHR (0.40) | DUTTSHRHIF1AFAAHTRPV1 | |
| SCHEMBL31240526 | 0.98 | TSHR (0.40) | DUTTSHRHIF1AFAAHTRPV1 | |
| SCHEMBL852468 | 0.94 | DUT (0.40) | DUTTSHRHIF1AFAAHTRPV1 | |
| SCHEMBL573170 | 0.85 | DUT (0.35) | DUT | |
| SCHEMBL8063404 | 0.82 | DUT (0.43) | DUT | |
| SCHEMBL26628157 | 0.82 | ALDH1A1 (0.39) | DUTTSHR | |
| SCHEMBL592575 | 0.82 | TSHR (0.38) | DUTTSHR | |
| SCHEMBL14245094 | 0.80 | DUT (0.42) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025132542-A1 | MACROCYCLIC OREXIN AGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025126118-A1 | LIPID COMPOUNDS AND USES THEREOF | PFIZER INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-4543853-A1 | OLIGONUCLEOTIDE DELIVERY ENHANCING COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS USING THE SAME | Ractigen Therapeutics (CN) | 2025-04-30 | — | — | EP | disclosed |
| CN-119654412-A | Oligonucleotide modulators that activate complement factor H expression | 中美瑞康核酸技术(南通)研究院有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119487000-A | Oligonucleotide delivery enhancing compounds, pharmaceutical compositions, and methods of use thereof | 中美瑞康核酸技术(南通)研究院有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119487192-A | Small activating nucleic acid molecules and their use in the treatment of hereditary angioedema | 中美瑞康核酸技术(南通)研究院有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20250027123-A1 | Compositions, Systems, and Methods for Performing a Mannich Cyclization Reaction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-23 | — | — | US | disclosed |
| CN-118619905-A | Butylphthalide derivative, preparation method and application thereof | 河南真实生物科技有限公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-116284188-B | Double-substrate inhibitor of DNA methyltransferase DNMT1 and application thereof | 南开大学 | 2024-07-26 | — | — | CN | disclosed |
| WO-2024001172-A1 | OLIGONUCLEOTIDE MODULATORS ACTIVATING COMPLEMENT FACTOR H EXPRESSION | RACTIGEN THERAPEUTICS (CN) | 2024-01-04 | — | — | WO | disclosed |
| WO-2009024492-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054466-A1 | Leukotriene B4 Inhibitors | DOMINIQUE ROMYR | 2009-02-26 | — | — | US | disclosed |
| US-7399775-B2 | β-amyloid protein production/secretion inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-15 | — | — | US | disclosed |
| US-7399775-B2 | β-amyloid protein production/secretion inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-15 | — | — | US | disclosed |
| US-20070293495-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-20 | — | — | US | disclosed |
| US-20070293495-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-20 | — | — | US | disclosed |
| US-7074822-B2 | Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-07-11 | — | — | US | disclosed |
| US-20050234109-A1 | to treat Alzheimer's disease,Down syndrome and the other diseases associated with amyloid deposition; thiomethane, sulfinylmethane or sulfonylmethane compounds; 5-Chloro-4-[(4-chlorophenylsulfonyl)-(2,5-difluorophenyl)methyl]-2-(4'-hydroxypiperidin-1'-yl)pyridine | DAIICHI PHARMACEUTICAL CO. LTD. (JP) | 2005-10-20 | — | — | US | disclosed |
| US-20050197386-A1 | Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-09-08 | — | — | US | disclosed |
| EP-1466898-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054466-A1 | Leukotriene B4 Inhibitors | LTB4R2, LTB4R, LTC4S | DUT 2534/4885TSHR 2676/4885HIF1A 3013/4885 |
| US-20050234109-A1 | to treat Alzheimer's disease,Down syndrome and the other diseases associated with amyloid deposition; thiomethane, sulfinylmethane or sulfonylmethane compounds; 5-Chloro-4-[(4-chlorophenylsulfonyl)-(2,5-difluorophenyl)methyl]-2-(4'-hydroxypiperidin-1'-yl)pyridine | APP, PSEN1, PSEN2 | DUT 3044/4885TSHR 2307/4885HIF1A 3179/4885 |
| US-20070293495-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | APP, IAPP, BACE1 | DUT 4582/4885TSHR 2368/4885HIF1A 4203/4885 |
| US-20050197386-A1 | Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them | PNLIP, CEL, LIPE | DUT 4534/4885TSHR 1411/4885HIF1A 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.